Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas (BIOVES)

June 29, 2026 updated by: Istituto Ortopedico Rizzoli

Feasibility Study for the Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas

The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

16

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Italy
    • BO
      • Bologna, BO, Italy, 40136
        • Recruiting
        • Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study aims to enroll patients of any gender who are being treated at the Rizzoli Orthopedic Institute in the following departments: Orthopedic and Traumatology Clinic III (with a primary focus on oncology), General and Thoracic Surgery (for both cancer and non-cancer patients), and Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies (for cancer patients only).

Description

Inclusion criteria for cancer patients

  • Male and female patients of any age diagnosed with Ewing sarcoma.
  • Signed, study-specific informed consent form for the BIOVES study (cancer patients)

Inclusion criteria for non-cancer patients

  • Male and female patients of legal age without a cancer diagnosis.
  • Signed, study-specific informed consent form for the BIOVES study (non-cancer patients)

Exclusion Criteria:

Patients who do not meet all inclusion criteria

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
oncological subject
Other: 3 blood samples
onco
non-oncological subjects
Other: one blood sample
non onco

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
characterisation of circulating biomarkers
Time Frame: at baseline (time 0); before surgery; after 6 months from surgery
search for circulating biomarkers from blood samples taken at three different time points
at baseline (time 0); before surgery; after 6 months from surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Ortopedico Rizzoli

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Study Registration Dates

First Submitted

June 29, 2026

First Submitted That Met QC Criteria

June 29, 2026

First Posted (Actual)

July 6, 2026

Study Record Updates

Last Update Posted (Actual)

July 6, 2026

Last Update Submitted That Met QC Criteria

June 29, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BIOVES

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcoma, Ewing

Clinical Trials on 3 blood samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe